Study Information
| Title: | A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer  |
| Status: | Recruiting participants |
| Conditions: | Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC |
| Interventions: | Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole |
| Health Topics: | Adenocarcinoma of the Lung, Lung Cancer Overview, Non-Hodgkin Lymphoma, Squamous cell carcinoma of the lung |
Contact Information
Pfizer Investigational Site
Boston, MA 02114
Pfizer Investigational Site
Boston, MA 02115